Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Verona Pharma plc (NASDAQ: VRNA).

Full DD Report for VRNA

You must become a subscriber to view this report.


Recent News from (NASDAQ: VRNA)

Verona Pharma Announces Publication of Key Paper on RPL554 in COPD in the European Respiratory Journal
LONDON, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today an...
Source: GlobeNewswire
Date: September, 06 2018 02:00
Verona Pharma plc's (VRNA) CEO Jan-Anders Karlsson on Q2 2018 Results - Earnings Call Transcript
Verona Pharma plc (VRNA) Q2 2018 Results Earnings Conference Call August 7, 2018, 08:00 AM ET Executives Stephanie Carrington - Investor Relations Jan-Anders Karlsson - Chief Executive Officer Piers Morgan - Chief Financial Officer Analysts Peter Welford - Jefferies Liana...
Source: SeekingAlpha
Date: August, 07 2018 14:42
Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2018
Significant progress with RPL554 as potential treatment for COPD and CF Recently initiated important Phase 2 trial as add-on to dual bronchodilator therapy for COPD maintenance treatment LONDON, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“...
Source: GlobeNewswire
Date: August, 07 2018 02:00
Verona Pharma Initiates Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment
This three-way crossover study will inform design of pivotal Phase 3 trials  Top line data expected first quarter 2019 LONDON, Aug. 01, 2018 (GLOBE NEWSWIRE) --  Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical...
Source: GlobeNewswire
Date: August, 01 2018 02:00
Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2018 and Provide Clinical Development Update
LONDON, July 26, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it will report its audited ...
Source: GlobeNewswire
Date: July, 26 2018 08:30
Verona Pharma to Present at 2018 Wedbush PacGrow Healthcare Conference
LONDON, July 24, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Jan-Anders Karlsson, ...
Source: GlobeNewswire
Date: July, 24 2018 08:30
Translate Bio prices upsized initial public offering
Translate Bio ( TBIO ) has priced an upsized initial public offering at $13/share , the midpoint of its range. More news on: Translate Bio, Vertex Pharmaceuticals Incorporated, Galapagos, Healthcare stocks news, IPOs, Read more ...
Source: SeekingAlpha
Date: June, 27 2018 18:47
Translate Bio Prepares For $100 Million U.S. IPO
Quick Take Translate Bio ( TBIO ) intends to sell shares of its common stock to raise $100 million from a U.S. IPO, according to an S-1/A registration statement . The firm is advancing a pipeline of mRNA-based treatment candidates to restore protein function in patients with cystic fi...
Source: SeekingAlpha
Date: June, 19 2018 13:47
Eloxx Pharma's ELX-02 shows encouraging action in preclinical CF studies; investors unmoved, shares down 11%
Investors appear unimpressed with preclinical data on Eloxx Pharmaceuticals' ( ELOX -10.6% ) lead candidate ELX-02 for the treatment of certain cystic fibrosis (CF) patients. The results were presented at the European Cystic Fibrosis Conference in Belgrade. More news on: Eloxx Pharmace...
Source: SeekingAlpha
Date: June, 08 2018 12:06
Blog Exposure - Blueprint Medicines Signed Collaboration Deal with CStone Pharma to Develop and Commercialize Avapritinib, BLU-554, and BLU-667 in Greater China
Stock Monitor: Verona Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / June 6, 2018 / If you want access to our free research report on Blueprint Medicines Corp. (NASDAQ: BPMC ), all you need to do is sign up now by clicking the following link www.active-investors.com/registra...
Source: ACCESSWIRE IA
Date: June, 06 2018 07:40

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0813.0312.9513.0312.511,310
2018-05-1716.1116.449916.7215.76357,846

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-181,2002,43649.2611Short
2018-12-1433100.0000Short
2018-12-12623623100.0000Short
2018-12-11100100100.0000Short
2018-12-101003,3802.9586Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on VRNA.


About Verona Pharma plc (NASDAQ: VRNA)

Logo for Verona Pharma plc (NASDAQ: VRNA)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: VRNA)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 08 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 04 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 04 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 18 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 29 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 22 2018
      Annual and transition report of foreign private issuers under sections 13 or 15(d)
      Filing Type: 20-FFiling Source: edgar
      Filing Date: February, 27 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 13 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 06 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: January, 26 2018

       

       


      Daily Technical Chart for (NASDAQ: VRNA)

      Daily Technical Chart for (NASDAQ: VRNA)


      Stay tuned for daily updates and more on (NASDAQ: VRNA)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: VRNA)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in VRNA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of VRNA and does not buy, sell, or trade any shares of VRNA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/